Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)

Author: Benzinga Newsdesk | August 05, 2024 03:42pm

HC Wainwright & Co. analyst Vernon Bernardino maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy, adjusts target to $19 from $2 (1-10 Reverse Stock Split).

Posted In: NRXP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist